RxDoctor Payments DataLook up a doctor →

Partha Nandi, MD

Gastroenterology · Troy, MINPI 1184605206

Payments from drug & device makers

$1,432,397in general payments, 2019–2025

Across 712 payments — averaging $2011.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$904K
  • Lilly USA, LLC$179K
  • AbbVie$158K
  • Phathom Pharmaceuticals, Inc.$152K
  • Medtronic$20K
  • Madrigal Pharmaceuticals$9K
  • plus $10K from 18 others

What the payments were for

  • Consulting fees$34,1549%
  • Speaking & faculty fees$285,69876%
  • Travel & lodging$46,96912%
  • Food & beverage$9,6583%
  • Education$640%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,432,397 in reported general payments places this provider in the 95th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$228,997
Medicare patients
563
Services billed
3,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$518,229
CreonLipase/Protease/Amylase26$77,769
VoqueznaVonoprazan Fumarate64$43,160
LinzessLinaclotide49$35,177
XifaxanRifaximin15$30,025
Mesalamine59$28,598
Esomeprazole Magnesium360$18,343
Dexlansoprazole DrDexlansoprazole31$13,657
Pantoprazole Sodium722$13,598
Sucralfate84$6,371
Rabeprazole Sodium87$5,027
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate15$4,114
Budesonide EcBudesonide24$2,081
Omeprazole135$1,956
Famotidine102$1,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$176$518,22919 claims
AbbVieCreon, Linzess$158,257$112,94675 claims
Phathom Pharmaceuticals, Inc.Voquezna$152,454$43,16064 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$154$30,02515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →